Hyperbaric Oxygen Therapy for Traumatic Brain Injury
(HOBIT Trial)
Trial Summary
What is the purpose of this trial?
This trial aims to find the best way to use hyperbaric oxygen treatment for patients with severe brain injuries. The treatment involves breathing pure oxygen at high pressure to help heal the brain. Researchers want to determine the safest and most effective settings for this treatment. Hyperbaric oxygen therapy is an existing and approved treatment for various medical conditions, including decompression sickness, air or gas embolism, and carbon monoxide poisoning.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of hyperbaric oxygen therapy for traumatic brain injury?
Research suggests that hyperbaric oxygen therapy (HBOT) may help improve oxygen supply to the injured brain, potentially reducing brain damage and improving outcomes for patients with traumatic brain injury. Studies indicate that HBOT might enhance the brain's ability to use oxygen more effectively after treatment, which could lead to better recovery.12345
Is hyperbaric oxygen therapy safe for humans?
Hyperbaric oxygen therapy is generally considered safe, but some people may experience side effects like ear or sinus pain, anxiety from being in a confined space, low blood sugar, oxygen toxicity, or seizures. These side effects are rare and often depend on individual factors and treatment conditions.36789
How is hyperbaric oxygen therapy different from other treatments for traumatic brain injury?
Hyperbaric oxygen therapy (HBOT) is unique because it involves breathing pure oxygen in a pressurized chamber, which increases oxygen supply to the brain and may help reduce brain damage. Unlike other treatments, HBOT is not a drug and works by creating a high-pressure environment that enhances oxygen delivery to injured brain tissue.123410
Research Team
Byron Gajewski, Ph.D.
Principal Investigator
University of Kansas Medical Center
Frederick K Korley, M.D., Ph.D.
Principal Investigator
University of Michigan
Gaylan L Rockswold, M.D., Ph.D.
Principal Investigator
Hennepin County Medical Center, Minneapolis
William Barsan, MD
Principal Investigator
University of Michigan
Eligibility Criteria
This trial is for people aged 16-65 with severe traumatic brain injury (TBI), defined as a Glasgow Coma Scale score of 3 to 8. They must be able to start treatment within 8-14 hours after admission, depending on whether they've had major surgery like craniotomy. Excluded are those who can't start treatment within 24 hours, have non-TBI related coma, penetrating head injuries, pre-existing neurological diseases, unstable spinal cord injury, fixed coagulopathy or severe hypoxia.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive hyperbaric oxygen treatment at varying pressures and durations, with or without Normobaric Hyperoxia (NBH), administered twice a day for 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including serious adverse events and therapeutic intensity level scores for controlling intracranial pressure
Treatment Details
Interventions
- Hyperbaric oxygen (Procedure)
- Usual Care (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hennepin Healthcare Research Institute
Lead Sponsor
Jennifer DeCubellis
Hennepin Healthcare Research Institute
Chief Executive Officer since 2020
M.A. from the Illinois School of Professional Psychology, B.A. from the University of Wisconsin-Madison
Dr. Eric W. Ling
Hennepin Healthcare Research Institute
Chief Medical Officer since 2024
MD from Northwestern Feinberg School of Medicine, MBA from the University of St. Thomas
Strategies to Innovate EmeRgENcy Care Clinical Trials Network
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Jordan Gladman
National Institute of Neurological Disorders and Stroke (NINDS)
Chief Medical Officer
MD from Harvard Medical School
Walter J. Koroshetz
National Institute of Neurological Disorders and Stroke (NINDS)
Chief Executive Officer since 2007
MD from the University of Chicago
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network
Collaborator